Integra LifeSciences Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Integra LifeSciences (IART) Tops Q2 EPS by 7c, Revenues Beat; Raises FY19 EPS Guidance, Affirms FY19 Revenue Outlook
July 24, 2019 5:50 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.73, $0.07 better than the analyst estimate of $0.66. Revenue for the quarter came in at $383.6 million versus the consensus estimate of $373.29 million.
Second Quarter 2019 Highlights
Reported revenues were $383.6 million, an increase of 4.8% compared to the second quarter of 2018, and organic revenues increased 6.6% over the prior-year quarter; - Reported revenues in the Codman Specialty Surgical segment increased 4.1% compared to the second quarter of 2018; - Reported revenues in the Orthopedics and Tissue Technologies segment increased 6.1% compared to the second quarter of 2018; - Foreign currency... More
